CEL-SCI Corp (CVM) - Financial and Strategic SWOT Analysis Review

CEL-SCI Corp (CVM) - Financial and Strategic SWOT Analysis Review


- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

CEL-SCI Corp (CEL-SCI) is a biotechnology company that carries out the research and development of new immunotherapy products for the treatment of various cancer, autoimmune, and infectious diseases. Its core capabilities include drug discovery, research, development and manufacture of compound biological substances. CEL-SCI’s lead candidate Multikine (leukocyte interleukin), is an investigational immunotherapy against cancer and human papilloma virus (HPV). The company is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 in hospitalized patients and vaccines, CEL-2000 and CEL-4000 for rheumatoid arthritis using Ligand Epitope Antigen Presentation System (LEAPS) technology platform. CEL-SCI is headquartered in Vienna, Virginia, the US.

CEL-SCI Corp Key Recent Developments

Aug 15,2024: CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
Jul 08,2024: CEL-SCI Appoints Robert Watson as Chairperson of the Board
Jun 06,2024: Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
May 16,2024: CEL-SCI Reports Second Quarter Fiscal 2024 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
CEL-SCI Corp - Key Facts
CEL-SCI Corp - Key Employees
CEL-SCI Corp - Key Employee Biographies
CEL-SCI Corp - Major Products and Services
CEL-SCI Corp - History
CEL-SCI Corp - Company Statement
CEL-SCI Corp - Locations And Subsidiaries
Head Office
Section 2 – Company Analysis
Company Overview
CEL-SCI Corp - Business Description
CEL-SCI Corp - Corporate Strategy
CEL-SCI Corp - SWOT Analysis
SWOT Analysis - Overview
CEL-SCI Corp - Strengths
CEL-SCI Corp - Weaknesses
CEL-SCI Corp - Opportunities
CEL-SCI Corp - Threats
CEL-SCI Corp - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
CEL-SCI Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Aug 15, 2024: CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
Jul 08, 2024: CEL-SCI Appoints Robert Watson as Chairperson of the Board
Jun 06, 2024: Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
May 16, 2024: CEL-SCI Reports Second Quarter Fiscal 2024 Financial Results
Apr 23, 2024: CEL-SCI Appoints Mario Gobbo to Its Board of Directors
Mar 06, 2024: CEL-SCI Issues Letter To Shareholders
Feb 15, 2024: CEL-SCI Reports First Quarter Fiscal 2024 Financial Results
Feb 06, 2024: CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
Dec 22, 2023: CEL-SCI Reports Fiscal 2023 Financial Results And Clinical & Corporate Developments
Oct 30, 2023: CEL-SCI Issues Letter To Shareholders
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
CEL-SCI Corp, Key Facts
CEL-SCI Corp, Key Employees
CEL-SCI Corp, Key Employee Biographies
CEL-SCI Corp, Major Products and Services
CEL-SCI Corp, History
CEL-SCI Corp, Key Competitors
CEL-SCI Corp, Ratios based on current share price
CEL-SCI Corp, Annual Ratios
CEL-SCI Corp, Annual Ratios (Cont...1)
CEL-SCI Corp, Interim Ratios
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
CEL-SCI Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
CEL-SCI Corp, Performance Chart (2019 - 2023)
CEL-SCI Corp, Ratio Charts
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings